01.17.2020 | AMR Industry Alliance 2020 Progress Report: Successes and Setbacks in Fighting Superbugs
AMR | The AMR Industry Alliance report provides a snapshot of the life science industry’s collective efforts in delivering on commitments to tackle the rise of antimicrobial resistance (AMR). Results from the Alliance’s survey of biotech, diagnostics, generic and large research-based biopharmaceutical companies are mixed. Positive results include sustained investment in early R&D and diagnostics for AMR-related products (including antibiotics, antifungals, vaccines) and strides in responsible manufacturing of antibiotics. Worryingly, low levels of investment for later and more costly stages of R&D for AMR-related products may mean that promising early-stage compounds will never reach patients unless governments put in place new mechanisms and incentives for antibiotic development.
01.16.2020 | Reframing the antimicrobial resistance crisis
THE HILL | Antimicrobials are special among classes of pharmaceuticals for several reasons, including their use in the treatment and prevention of infections, and also as a vital component of the medical countermeasures to be used during a biological attack. In this opinion piece, authors Dr. Amesh A. Adalja and Greg Salmieri argue that the antimicrobial market is in crisis and governments need to radically change the philosophical and moral way they view the development and delivery of new products to patients. The treatment and control of infectious diseases is historically one of the most civilizing and life-enhancing activities undertaken by humans. It deserves to be recognized and monetarily valued as such.
01.14.2020 | The Broken Business of Antibiotics – a WSJ podcast on economic problems faced by antibiotics companies
WALL ST JOURNAL and GIMLET MEDIA | WSJ’s Denise Roland explains the complex challenges facing antibiotics companies attempting to bring urgently needed new antibiotics onto the market. 17 minutes with ads. The world desperately needs new antibiotics to tackle the rising threat of drug-resistant superbugs, but there is little reward for doing so.
01.12.2020 | Estimating the Size of the U.S. Market for New Antibiotics with Activity against Carbapenem-Resistant Enterobacteriaceae
AMERICAN SOCIETY FOR MICROBIOLOGY | New antibiotics with activity against carbapenem-resistant Enterobacteriaceae (CRE) improve outcomes of CRE-infected patients. However, companies developing these drugs have faced financial difficulties. Sales of ceftazidime-avibactam, meropenem-vaborbactam, and plazomicin in the United States totaled $101 million from February 2018 to January 2019. The authors estimate that the current annual U.S. market for new anti-CRE antibiotics is an estimated $289 million. Without new antibiotic development models and/or reimbursement reform, the majority of anti-CRE drugs will be commercially inviable.
01.08.2020 | ContraFect stock price doubles after Pfizer buys $3 million stake in company
BARRON’S | Like all publicly traded antibacterial product developers, ContraFect had a rough year in 2019. The biotech firm (ticker: CFRX), which is focused on discovering and developing so-called direct lytic agents to treat life-threatening infectious diseases, including staphylococcus that is resistant to antibiotics, saw its stock price fall to 27 cents in August from $1.53 at the end of 2018. ContraFect, which has two projects funded by CARB-X, got a boost in December when Pfizer took a $3-million stake in the company. Its stock price has now bucked the trend among antibacterial product developers and is rallying.
01.07.2020 | Antibiotics need a special place in the US drug pricing debate
STAT NEWS | In this commentary, Pew Charitable Trust’s Allan Coukell warns that the rise of antibiotic resistance is inevitable as pathogens evolve to resist every existing antibiotic, and that if we allow the pipeline to dwindle, the price won’t be just in dollars, it will also be in lives lost. He urges the US congress to move swiftly to enact a package of economic incentives ‘to reinvigorate the stagnant pipeline of antibiotics. He also urges the US government to move forward with the Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019, which could help ease the pressures working against new antibiotics in the US healthcare system. No single policy change will stem the exodus of investment from research on new antibiotics. But incentives such as these, combined with existing federal and public-private programs to defray research and development costs, are essential to turning the tide.
01.05.2020 | Antibiotic Marketing and Pipeline Shortages in the Era of Stewardship: An Industry Perspective
CONTAGIONLIVE | An industry overview of the economic and market challenges that antibiotics developers face, and the growing unmet medical need from drug-resistant bacterial infections.
01.05.2020 | How to Combat Antibiotic Resistance: 5 Priorities for 2020
PEW CHARITABLE TRUSTS | PEW’s antibiotic-resistance team examines the latest CDC findings on drug-resistant infections in the US and proposes 5 ways to combat resistance in 2020. The CDC report underscores the urgency of the threat, and need to maintain the fight against superbugs